FDA Approves First New Drug to Treat and Slow Progression of Duchenne Muscular Dystrophy

• FDA approves new drug, Duvyzat (givinostat), to treat Duchenne Muscular Dystrophy (DMD) in patients 6+ years old • Duvyzat is the first nonsteroidal treatment approved for all genetic variants of DMD • Duvyzat works by reducing inflammation and muscle loss • In clinical trials, Duvyzat showed improved muscle function and slowed disease progression compared to placebo • Common side effects include diarrhea, abdominal pain, low platelets, nausea, high triglycerides, and fever